AstraZeneca partners with MGH Healthcare Ltd. to bring life-changing medicines to patients in Bangladesh


MGH HealthCare and AstraZeneca Partnership Inaugurated by The Two Leaders of the Companies

AstraZeneca, leading global science-led biopharmaceutical company of Swedish-British origin, announces its partnership with MGH Healthcare Limited to provide convenient and reliable access to AstraZeneca medicines in Bangladesh. 

Swedish Ambassador Ms. Charlotta Schlyter

The partnership was inaugurated under the auspices of Swedish Ambassador Ms. Charlotta Schlyter and British High Commissioner Mr. Robert Chatterton Dickson, in the presence of Md. Ruhul Amin, Director, Directorate General Drug Administration, Government of People’s Republic of Bangladeshtogether with a panel session on “Driving access to innovative medicines to improve patient outcomes in Bangladesh”, at a public event hosted today by Business Sweden – The Swedish Trade and Invest Council in Dhaka.

British High Commissioner Mr. Robert Chatterton Dickson





Swedish Ambassador Charlotta Schlyter and British High Commissioner Robert Chatterton Dickson delivered remarks on the potential for further healthcare cooperation with Bangladesh. Leading healthcare officials and physicians were in attendance and contributed their valuable insights to the conversation.

Through this partnership, AstraZeneca and MGH Healthcare Limited, aim to achieve our shared ambition to “make our science accessible” as it will help us to deliver innovative treatments to all patients who need it. AstraZeneca is a leader in the treatment of Non-Communicable Diseases (NCDs) such as Cancer and Cardiovascular-Metabolic-Renal Diseases which are prevalent in Bangladesh.  AstraZeneca is committed to improve patient outcomes through scientific discovery and collaborations,” said Nitin Kapoor, Company President AstraZeneca.


Panel Members Discussed "Driving access to innovative medicines to improve patient outcomes in Bangladesh"

Bangladesh has seen a high increase of mortality due to NCDs, with cardiovascular disease (30%), cancer (12%) and chronic respiratory disease (10%) as important causes of death.**[1] Recognizing that government and industry have a shared responsibility to deliver high-quality healthcare to the people of Bangladesh, AstraZeneca and MGH Healthcare Limited are proud to support patients through this new partnership. Together, they will increase awareness amongst physicians and patients about the science behind innovative treatments and will increase access to innovative treatments to make a difference to patients in Bangladesh.

The Distinguished Members of AstraZeneca, Business Sweden and MGH Healthcare

Founder and group CEO of MGH, Anis Ahmed

Founder and group CEO of MGH, Anis Ahmed said, “With the blessings of Allah (SWT), and due to the outstanding leadership of Honorable Prime Minister Sheikh Hasina, Bangladesh’s economy has experienced 11 years of non-stop growth of over 7% - a testament of what stability, and a leader’s vision can bring into a young nation like Bangladesh. MGH is simply honored, and humbled to partner AstraZeneca in Bangladesh”. 

He also added, “Through our valued partnership with AstraZeneca, we aim to serve and provide access to right medicines and offer best care to our Bangladesh patients. MGH Healthcare Limited, with its extensive sales, distribution network, robust quality facilities and healthcare intelligence, will support patients in accessing the AstraZeneca innovative medicines all across Bangladesh. We simply want Bangladeshis to have access to authentic, and world class medicines.”

The AstraZeneca and MGH Healthcare Team Along With Distinguished Guest Doctors and Medical Professionals


AstraZeneca, is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Oncology and Cardiovascular, Renal & Metabolism. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection.

AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca now stands ready to support Bangladesh on some of the key health concerns in the country, with expertise and high-quality treatments within oncology, cardiovascular and metabolic illnesses.

About MGH Healthcare Limited
MGH Healthcare Limited is renowned for wide distribution network services which integrate and manage the entire global value chain between suppliers, manufacturers, brand owners and customers like AstraZeneca, Omron, and Sanofi.

With footprint in 18 countries around the globe, MGH is a Multinational Conglomerate delivering service excellences in Fast Fashion, Automotive, Healthcare Supply Chain management of Global Brands, Total Cargo Management of Legacy, Budget Airlines, Global Distribution Systems (GDS) of Travel Port, along with Radio FM, Branded Food Franchises, Commercial Banking, Tea Plantations, and Ride-Sharing businesses, respectively. MGH is looking forward to its new office openings in the Kingdom of Saudi Arabia, and in China in  2019.

About Business Sweden
Business Sweden - The Swedish Trade and Invest Council is governed by the Swedish Ministry of Foreign Affairs and Swedish Export Industry Association. Business Sweden is tasked to promote bilateral trade and investments between Sweden and other countries. 

In the News: 

1. AstraZeneca enters Bangladesh market (The Daily Star)
2. New Swedish medicines in Bangladesh (The Financial Express)
3. অ্যাস্ট্রাজেনেকার ওষুধ বাজারজাত করবে এমজিএইচ (Naya Diganta)
4. দেশে ক্যান্সারের ওষুধ আনলো এমজেএইচএল হেলথ কেয়ার (The Daily Inqilab)

[1] ** WHONoncommunicable diseases country profiles 2018 https://www.who.int/nmh/publications/ncd-profiles-2018/en/ 

Comments

Popular posts from this blog

MGH Group Participates with Three Stalls at the 27th US Trade Show

Logistics made Simple - Shipping Process

Things to Consider for a Successful Shipment